Cover Image
市場調查報告書

肌肉痙攣:開發平台分析

Muscle Spasm - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 227545
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
肌肉痙攣:開發平台分析 Muscle Spasm - Pipeline Review, H1 2015
出版日期: 2015年04月15日 內容資訊: 英文 42 Pages
簡介

肌肉痙攣是指肌肉隨著收縮帶來劇烈的疼痛。症狀有背痛、脊椎彎曲、頸部疼痛或僵硬、肩膀或手臂疼痛、背脊發硬、單邊腳疼痛或沒有感覺,或是微微發疼。危險因素有僵直性脊椎炎的併發症,膽囊結石,腎臟結石,腎盂腎炎等。。

本報告提供肌肉痙攣的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。以及最新的新聞和發表等資訊。

簡介

  • 調查範圍

肌肉痙攣 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

企業開發中的產品

治療藥的開發企業

  • Eisai
  • Omeros Corporation
  • Sanochemia Pharmazeutika AG

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (diclofenac sodium + eperisone)
  • (ketoprofen + nifedipine)
  • Drug for Neuromuscular Disorders and Muscle Cramps
  • NVP-1102
  • tolperisone

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6662IDB

Summary

Global Markets Direct's, 'Muscle Spasm - Pipeline Review, H1 2015', provides an overview of the Muscle Spasm's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Spasm, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Spasm and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Muscle Spasm
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Muscle Spasm and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Muscle Spasm products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Muscle Spasm pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Muscle Spasm
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Muscle Spasm pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Muscle Spasm Overview
  • Therapeutics Development
    • Pipeline Products for Muscle Spasm - Overview
    • Pipeline Products for Muscle Spasm - Comparative Analysis
  • Muscle Spasm - Therapeutics under Development by Companies
  • Muscle Spasm - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Muscle Spasm - Products under Development by Companies
  • Muscle Spasm - Companies Involved in Therapeutics Development
    • Eisai Co., Ltd.
    • Omeros Corporation
    • Revance Therapeutics, Inc.
    • Sanochemia Pharmazeutika AG
  • Muscle Spasm - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diclofenac sodium + eperisone) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (ketoprofen + nifedipine) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Agonize TRPA1 and TRPV1 for Neuromuscular Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVP-1102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RT-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tolperisone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Muscle Spasm - Recent Pipeline Updates
  • Muscle Spasm - Dormant Projects
  • Muscle Spasm - Product Development Milestones
    • Featured News & Press Releases
      • Nov 12, 2013: Sanochemia Receives First Patent For Japan
      • Nov 23, 2012: Sanochemia Receives US Notice Of Allowance For Manufacture Of Tolperisone
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Muscle Spasm, H1 2015
  • Number of Products under Development for Muscle Spasm - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Muscle Spasm - Pipeline by Eisai Co., Ltd., H1 2015
  • Muscle Spasm - Pipeline by Omeros Corporation, H1 2015
  • Muscle Spasm - Pipeline by Revance Therapeutics, Inc., H1 2015
  • Muscle Spasm - Pipeline by Sanochemia Pharmazeutika AG, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Assessment by Combination Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Muscle Spasm Therapeutics - Recent Pipeline Updates, H1 2015
  • Muscle Spasm - Dormant Projects, H1 2015

List of Figures

  • Number of Products under Development for Muscle Spasm, H1 2015
  • Number of Products under Development for Muscle Spasm - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Assessment by Combination Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top